AAPG
Q1 2027 EPS Estimate
$-0.33
Mar 31, 2027
Revenue Estimate
$49M
FY2029E EPS$3.84
FY2030E EPS$10.64

Analyst Sentiment

Wall St. Consensus
Buy
1 analyst·Low coverage
75
Score
1 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
1100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$40.00
+133.9%
Consensus
$40.00
+133.9%
Bull
$40.00
+133.9%
12-Month Target Range1 analyst
$40.00$40.00$40.00
Current $17.10Consensus
Current Price
$17.10
Upside to Consensus
$22.90

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+148.61%
EPS
FY2028
Rev+33.20%
EPS
FY2029
Rev+118.41%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$799M$1.99B$2.65B$5.78B$9.02B
Low$680M$512M$1.54B$3.37B$5.26B
High$1.11B$4.82B$4.74B$10.36B$16.16B
EBITDA Avg$-525M$156M$370M$1.43B$2.85B
Low$-675M$-7.43B$178M$1.20B$2.20B
High$-267M$3.81B$471M$1.88B$4.09B
EBIT Avg$-667M$-143M$-116M$504M$1.27B
Low$-817M$-7.73B$-308M$270M$620M
High$-409M$3.51B$-15M$950M$2.50B
Net Income Avg$-738M$-214M$-187M$342M$947M
Low$-888M$-7.80B$-379M$157M$434M
High$-480M$2.72B$-86M$695M$1.92B
EPS Avg$-8.29$-2.40$-2.10$3.84$10.64
Low$-9.98$-87.65$-4.26$1.76$4.87
High$-5.39$30.54$-0.96$7.80$21.59
Analysts (Rev / EPS)5 / 46 / 42 / 24 / 13 / 1
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$432M$1.59B$512M$310M$310M$356M$425M$393M
Low$432M$1.59B$512M$310M$310M$356M$425M$393M
High$432M$1.59B$512M$310M$310M$356M$425M$393M
EBITDA Avg$82M$108M$124M$-427M$-416M$-168M$-209M$-76M
Low$82M$108M$124M$-427M$-416M$-168M$-209M$-76M
High$82M$108M$124M$-427M$-416M$-168M$-209M$-76M
EBIT Avg$31M$31M$31M$-508M$-514M$-254M$-315M$-166M
Low$31M$31M$31M$-508M$-514M$-254M$-315M$-166M
High$31M$31M$31M$-508M$-514M$-254M$-315M$-166M
Net Income Avg$11M$10M$11M$-526M$-531M$-271M$-333M$-184M
Low$11M$10M$11M$-526M$-531M$-271M$-333M$-184M
High$11M$10M$11M$-526M$-531M$-271M$-333M$-184M
EPS Avg$0.11$0.11$0.11$-5.63$-5.74$-2.91$-3.59$-1.97
Low$0.11$0.11$0.11$-5.63$-5.74$-2.91$-3.59$-1.97
High$0.11$0.11$0.11$-5.63$-5.74$-2.91$-3.59$-1.97
Analysts (Rev / EPS)1 / 11 / 11 / 11 / 11 / 11 / 11 / 11 / 1

Earnings Surprises

Recent Analyst Actions

Apr 24, 2026Deutsche Bank
Ascentage Pharma initiated with a Buy at Deutsche Bank
Target:$40.00
+79.1%from $22.34
Dec 4, 2025Oppenheimer
Ascentage Pharma initiated with an Outperform at Oppenheimer
Target:$45.00
+48.4%from $30.33
Nov 24, 2025Truist Financial
Ascentage Pharma initiated with a Buy at Truist
Target:$51.00
+66.4%from $30.64
Nov 5, 2025Piper Sandler
Piper Sandler Starts Ascentage Pharma Group (AAPG) at Overweight
Target:$48.00
+44.4%from $33.25
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.